Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mikaela Dougherty"'
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adi
Externí odkaz:
https://doaj.org/article/960a1f44bc504332b44f084b1e622c37
Autor:
Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Claudia Brady, Marina Kremyanskaya, Michal Bar-Natan, Alla Keyzner, Bridget K. Marcellino, Janice Gabrilove, Shyamala C. Navada, Lewis R. Silverman, Siraj M. El Jamal, John Mascarenhas, Alan H. Shih
Publikováno v:
HemaSphere, Vol 5, Iss 4, p e549 (2021)
Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). Th
Externí odkaz:
https://doaj.org/article/bab19e331abb4530ad2b753a61fd89a0
Autor:
Michal Bar-Natan, John Mascarenhas, Aaron T. Gerds, Ruben Mesa, Vikas Gupta, Marina Kremyanskaya, Mikaela Dougherty, Frank Fabris, Kathryn Johnson, Ashley Yu, Heidi E. Kosiorek, Carolyn Mead-Harvey, Amylou C. Dueck, Ronald Hoffman, Raajit K Rampal
Publikováno v:
Blood. 140:3988-3990
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fad123e6461b39629c54316e6f98ed20
https://doi.org/10.1182/blood-2022-164678
https://doi.org/10.1182/blood-2022-164678
Autor:
Alan H. Shih, Mikaela Dougherty, Claudia Brady, Shyamala C. Navada, Bridget K. Marcellino, Gillian Sanchez, Siraj M. El Jamal, John Mascarenhas, Michal Bar-Natan, Marina Kremyanskaya, Alla Keyzner, Janice Gabrilove, Tina Czaplinska, Lewis R. Silverman, Jonathan Feld, Douglas Tremblay
Publikováno v:
HemaSphere, Vol 5, Iss 4, p e549 (2021)
HemaSphere
HemaSphere
Hypomethylating agents (HMAs) in combination with venetoclax have been widely adopted as the standard of care for patients who cannot tolerate induction chemotherapy and for patients who have relapsed/refractory (R/R) acute myeloid leukemia (AML). Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::848278b16e4bbb2038d74cc75b8e7a28
http://journals.lww.com/10.1097/HS9.0000000000000549
http://journals.lww.com/10.1097/HS9.0000000000000549
Autor:
John Mascarenhas, Alla Keyzner, Tina Czaplinska, Marina Kremyanskaya, Alan H. Shih, Mikaela Dougherty, Gillian Sanchez, Michal Bar-Natan, Douglas Tremblay, Jonathan Feld
Publikováno v:
Leukemia Research. 98:106456
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a650b6937ec3f66a3b3c5eb6d7f583e8
https://doi.org/10.1016/j.leukres.2020.106456
https://doi.org/10.1016/j.leukres.2020.106456